Originator versus biosimilar adalimumab in hidradenitis suppurativa: A multicenter real-world analysis of clinical response, maintenance of response, and switching
{{output}}
Background: Adalimumab is a mainstay treatment for hidradenitis suppurativa (HS); however, high-costs limit accessibility. While biosimilars offer an affordable alternative, concerns remain regarding clinical equivalence and the ... ...
